文献速递细菌感染、耐药与抗菌药物医院感染防控新发突发、热带与寄生虫病

利用替代来源的抗微生物耐药数据支持低资源地区监测

Harnessing alternative sources of antimicrobial resistance data to support surveillance in low-resource settings.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

本文探讨低资源地区抗微生物耐药(AMR)监测数据生成与共享的紧迫挑战,指出常规监测能力建设需时,而制药和学术机构及私人实验室已积累大量耐药数据。文章分析这些未开发数据来源作为短期桥梁方案的利弊、可及性障碍,并提出数据映射、共享机制、支持国家行动计划等关键行动。

要点

  • 低资源地区常规AMR监测能力建设需时,替代数据源可作短期桥梁
  • 制药、学术及私人实验室已积累大量耐药感染数据但未充分利用
  • 需建立数据共享机制并支持WHO全球AMR监测系统使用

核心结论

  • 利用制药、学术和私人实验室的未开发数据可作为低资源地区AMR监测的短期解决方案。

研究设计与样本

  • 本文为综述/观点文章,探讨低资源地区AMR监测替代数据来源的利用。

主要发现

  • 制药和学术initiatives已产生大量低资源地区AMR和耐药感染数据,私人实验室也生成大量数据。
  • 常规监测能力建立前,这些未开发数据可填补监测空白。

关键数值与推荐

  • 需开展数据映射、建立数据共享机制、利用数据支持国家行动计划。
  • 需促进WHO全球AMR监测系统获取和使用数据,并创新数据捕获、分析和共享。

临床怎么用

  • 临床和公共卫生机构可探索利用替代数据源补充常规监测,并参与数据共享机制。

局限性

  • 文章讨论了这些数据来源的益处和局限性,但未具体量化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

One of the most pressing challenges facing the global surveillance of antimicrobial resistance (AMR) is the generation, sharing, systematic analysis and dissemination of data in low-resource settings. Numerous agencies and initiatives are working to support the development of globally distributed microbiology capacity, but the routine generation of a sustainable flow of reliable data will take time to establish before it can deliver a clinical and public health impact. By contrast, there are a large number of pharma- and academia-led initiatives that have generated a wealth of data on AMR and drug-resistant infections in low-resource settings, together with high-volume data generation by private laboratories. Here, we explore how untapped sources of data could provide a short-term solution that bridges the gap between now and the time when routine surveillance capacity will have been established and how this could continue to support surveillance efforts in the future. We discuss the benefits and limitations of data generated by these sources, the mechanisms and barriers to making this accessible and how academia and pharma might support the development of laboratory and analytical capacity. We provide key actions that will be required to harness these data, including: a mapping exercise; creating mechanisms for data sharing; use of data to support national action plans; facilitating access to and use of data by the WHO Global Antimicrobial Resistance Surveillance System; and innovation in data capture, analysis and sharing.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Ashley EA, Shetty N, Patel J, et al. Harnessing alternative sources of antimicrobial resistance data to support surveillance in low-resource settings. J Antimicrob Chemother. 2019. PMID: 30544186. doi:10.1093/jac/dky487

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。